Mannose supplementation in PMM2-CDG.

Taday R, Park JH, Grüneberg M, DuChesne I, Reunert J, Marquardt T

Research article (journal) | Peer reviewed

Abstract

In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper "Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)" has shown that further investigation of mannose in PMM2-CDG is worthwhile alongside other treatment options and should not be dismissed off-hand without the willingness to prove or disprove it in controlled prospective clinical trials.

Details about the publication

JournalOrphanet Journal of Rare Diseases
Volume16
Issue1
Page range359-359
StatusPublished
Release year2021 (11/09/2021)
Language in which the publication is writtenEnglish
DOI10.1186/s13023-021-01988-x
KeywordsCongenital Disorders of Glycosylation; Dietary Supplements; Humans; Mannose; Phosphotransferases (Phosphomutases); Prospective Studies

Authors from the University of Münster

Park, Julien Heinrich
University Children's Hospital - Department for General Paediatrics